| Similar Articles |
|---|
 |
Chemistry World
June 23, 2014
Phillip Broadwith |
Shire fends off AbbVie takeover bid Shire is the latest pharmaceutical company to be targeted for a multi-billion dollar takeover deal from a firm looking to transfer its tax residence outside the US.   |
Chemistry World
October 17, 2014
Phillip Broadwith |
AbbVie backs out of Shire deal AbbVie has recommended its shareholders vote against the deal, and if that happens, the company will pay Shire a break-off fee of $1.6 billion. |
Chemistry World
November 4, 2015
Phillip Broadwith |
Shire to buy cardiovascular specialist Dyax The deal gives Shire access to Dyax's portfolio of approved and developmental drugs for treating hereditary angioedema. |
Chemistry World
July 25, 2014
Anthony King |
Pharma firms rush to escape US tax shackles US drug company AbbVie has persuaded Hampshire-based, Irish-headquartered Shire to enter a mega-merger. The enlarged firm will cut its US tax bill. |
The Motley Fool
October 30, 2006
Brian Lawler |
Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note. |
The Motley Fool
October 9, 2007
Brian Lawler |
Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises. |
The Motley Fool
May 25, 2011
David Williamson |
Pay Attention to Shire The British ADHD medicine maker is busy making big moves. |
Chemistry World
March 11, 2015
Rebecca Trager |
Mergers and moves trigger pharma layoffs Downsizing in the pharmaceutical industry is discussed. |
Chemistry World
January 26, 2015
Phillip Broadwith |
Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion. |
The Motley Fool
February 26, 2007
Brian Lawler |
Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition. |
Pharmaceutical Executive
August 1, 2013
William Looney |
Succinctly Shire: An Interview with CEO Flemming Ornskov Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate. |
